Montana’s Experimental Treatment Centers Put FDA Oversight on Pause

I’ve spent enough years watching organizations invent “temporary exceptions that somehow become permanent to recognize the pattern when a state does it with medicine.

Montana did not quietly tweak a form. Through Senate Bill 422 (2023) and Senate Bill 535 (2025), the state broadened Right to Try beyond terminal illness and then built a commercial licensing framework for Experimental Treatment Centers—clinics that can recommend and administer investigational drugs, biologics, or devices that have completed Phase I trials but lack full FDA approval. Implementing rules from the Montana Department of Public Health and Human Services took effect July 25, 2026. That is the sober version of the story the earlier stub turned into a cloud-compliance metaphor.

What the law actually does

Phase I trials are small, dose-finding safety studies. Most candidates that clear Phase I never reach approval; efficacy and rarer risks show up later. Federal Right to Try (2018) and FDA expanded access already give pathways for seriously ill patients. Montana went further: eligibility no longer requires a terminal diagnosis, and licensed centers may provide qualifying treatments for compensation, subject to state rules on staffing, adverse-event reporting, informed consent, and facility standards.

Patients still must consider approved options, get a provider recommendation, and give written informed consent. State licensing is not FDA approval. It is a parallel gate—one that lives in Helena, not Silver Spring.

Primary sources worth reading yourself:

• [Montana Free Press / Capitol Tracker on SB 422](https://apps.montanafreepress.org/capitol-tracker-2023/bills/sb-422/)
• [Montana DPHHS final rulemaking on Experimental Treatment Centers (MAR 2026-427)](https://dphhs.mt.gov/assets/rules/2026-427-Adp-Arm.pdf)
• [FDA overview of Expanded Access](https://www.fda.gov/news-events/public-health-focus/expanded-access)
• Medical Daily’s summary of the July 2026 rule go-live: [Montana licenses clinics for FDA-unapproved treatments](https://www.medicaldaily.com/montana-experimental-treatment-centers-licensing-fda-unapproved-477773)

Why a sysadmin brain flinches

When I ran IT shops, the scariest phrase was we’ll just run it in production; we tested it on a few users.” Phase I is that sentence in lab coats. Useful as a first filter. Not a substitute for the later trials that kill most candidatesfor good reasons.

Montana’s model creates a split control plane: federal labeling and interstate commerce rules on one side, state-licensed commercial administration on the other. EHRs, pharmacy systems, and claims pipelines were built around FDA status codes, NDC catalogs, and coverage rules that assume a single authority. Now you can have a product that is “legal here under MCA Title 50” and “not approved for general use” under federal law at the same time. That is not a clever API design. That is two systems of record with overlapping jurisdiction and different failure modes.

From a debugging lens, the questions I want answered are boring and important:

1. How do adverse events get reported, to whom, and how fast do patterns surface?
2. What happens when a Montana-administered product follows a patient into an Ohio hospital?
3. How do insurers, PBMs, and Medicare treat these encounters?
4. What audit trail exists if a center’s “documented clinical evidence” later falls apart?

If those answers are muddy, you don’t have innovation—you have an incident waiting for a spreadsheet.

Patient autonomy vs. system integrity

I get the human argument. If approved options have failed and you understand the risks, waiting for a multi-year Phase III queue can feel like cruelty with a filing cabinet. Right to Try was sold on that emotion for a reason.

But commercial licensing changes the incentive structure. Centers can charge. Patients can shop. Marketing will outrun pharmacovigilance unless the state forces the opposite. SB 535’s requirement that centers put a slice of profit toward free care or premium support is a political patch, not a safety architecture.

Humorously—and I mean the dry kind—Montana just stood up what IT people call a shadow IT environment for medicine: officially acknowledged, locally governed, and permanently awkward for the enterprise standard.

What operators and policymakers should watch

• **Data integrity:** Trial-like outcomes without trial-like controls will pollute real-world evidence used by AI diagnostics and payers.
• **Supply chain:** National distributors and compounding networks will get asked to move products that live in a gray zone; compliance teams will hate the ambiguity.
• **Federal response:** Expect pressure for FDA guidance, interstate commerce cases, or CMS coverage clarifications. States rarely get the last word when products cross borders.
• **Copycats:** If Montana’s centers attract capital, other states will draft lookalikes. Policy fragments faster than software patches.

Bottom line

Montana built a real regulatory experiment: Phase I as the entry ticket, state licenses as the storefront, informed consent as the EULA. Whether that expands access for people who have run out of options or becomes a loophole machine depends entirely on enforcement quality—adverse-event reporting, honest marketing, and whether “considered approved options means a serious conversation or a checkbox.

Im not anti-patient choice. I’m anti-systems that skip the hard validation step and then act surprised when production breaks. Medicine deserves better change control than a weekend deploy.

Steve Miller — Mason, Ohio. Former programmer, sysadmin, and IT manager. Still allergic to “we’ll patch it later.”